Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Drug Disease Model Resources (DDMORE)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: United Kingdom,Sweden,Germany,Netherlands,Italy,France,Italy,Germany,France,Spain,Israel,Switzerland,Sweden,Germany,Denmark,France,Belgium,Germany,France,United Kingdom,United Kingdom
Call:  (IMI-JU-02-2009, 2009)
Start date: 2011-03-01
End date: 2016-08-31
Duration (months): 66.0
Total project cost (EUR): 23063274.0
EU funding (EUR): 10399426.0
Participants: 28
Project status: CLOSED

Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quantitative decision-making. M&S facilitates the continuous integration of available information related to a drug or disease into constantly-evolving mathematical models capable of describing and predicting the behaviour of studied systems to address the questions researchers, regulators, and public health care bodies face when bringing drugs to patients. The full adoption of MBDD is frustrated by a lack of common tools, languages and ontologies for M&S, which often leads to inefficient reuse of data and duplication of effort by academic, industrial and regulatory stakeholders. The Drug Disease Model Resources (DDMoRe) consortium’s strategy will have standards as its core: a newly developed common definition language for data, models and workflows, along with an ontology based standard for storage and transfer of models and associated metadata. A drug and disease model library will be developed as a public resource. Its flexibility and power will be showcased by the addition of “proof of concept” drug and disease models from key therapeutic areas such as diabetes and oncology. An open-source interoperability framework will be the backbone for the integration of M&S applications into seamless, standardized but flexible workflows. Initially, currently-used tools (e.g. NONMEM, WinBUGS, Matlab, R) will be integrated into the framework. From the outset resources will also be dedicated to new application development which will be steered by identified gaps in the M&S software ecosystem. The DDMoRe project’s standards and tools – intended as the gold standard for future collaborative drug and disease M&S - will be supported by comprehensive training and will be made publicly accessible.

Keywords: modelling & simulation,model library,pharmacometrics standards,systems biology,pk/pd,ontology
DIabetes REsearCh on patient sTratification (DIRECT)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Germany,United Kingdom,United Kingdom,Italy,Denmark,Germany,Germany,Spain,United Kingdom,Sweden,France,Netherlands,Denmark,Finland,Sweden,United Kingdom,United Kingdom,Switzerland,United Kingdom,Germany,Netherlands,France,France,Germany
Call:  (IMI-JU-03-2010, 2010)
Start date: 2012-02-01
End date: 2019-07-31
Duration (months): 90.0
Total project cost (EUR): 46484127.0
EU funding (EUR): 21388643.0
Participants: 26
Project status: CLOSED

The overarching aims of the DIRECT consortium, consisting of 20 leading academic groups in diabetes and 5 EFPIA companies, are to identify biomarkers that address current bottlenecks in diabetes drug development and to develop a stratified medicines approach to treatment of type 2 diabetes with either existing or novel therapies. There is heterogeneity in who develops diabetes, the rate at which their subsequent diabetes progresses, how they respond to diabetes therapy and who develops micro- and macrovascular complications. In the DIRECT consortium we propose to identify biomarkers to identify subtypes with rapid diabetes development and progression and altered response to diabetes treatments, and develop and use these biomarkers in clinical trials. Two phenotyping work packages will focus on glycaemic deterioration and therapeutic response. For each, the DIRECT consortium brings considerable existing resource, which will be augmented by large-scale prospective cohort collection with intensive physiological and imaging phenotyping. Additional data will be added, such as existing studies on acute response to intravenous beta-cell secretagogues, and functional genomics on human islets, liver, muscle and adipose tissue, to maximise the power and utility of an innovative integrated biology approach. To enable computational multi-level integration across phenotypes and data types, a robust and secure data repository will be developed with strict data governance. As the ultimate aim of DIRECT is patient stratification, biomarkers arising from the discovery work will be used to design one or more prospective clinical trials. These will validate the biomarker(s) of interest, and establish utility in clinical practice and/or trial design and drug development. As a result, this consortium offers considerable potential to achieve major progress towards a personalized medicines approach to the treatment of type 2 diabetes.

Keywords: diabetes,personalised medicine,biomarkers,stratification
Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC) (STEMBANCC)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Switzerland,United Kingdom,Germany,United Kingdom,Germany,France,Iceland,United Kingdom,Denmark,United Kingdom,Germany,Germany,Germany,United Kingdom,Austria,France,United Kingdom,Germany,Israel,France,Sweden,Germany,Germany,Belgium,Germany,Denmark,Finland,France,United Kingdom,Sweden
Call:  (IMI-JU-04-2011, 2011)
Start date: 2012-10-01
End date: 2018-03-31
Duration (months): 66.0
Total project cost (EUR): 55010480.0
EU funding (EUR): 26000000.0
Participants: 38
Project status: CLOSED

StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug discovery pipeline based upon human induced pluripotent stem cells (hiPSC). This unrivalled opportunity will address the pressing therapeutic need in neurodegeneration, neurodysfunction and diabetes. We have immediate access to richly phenotyped subjects with a wealth of clinical data. Furthermore our cohorts include genetic and genome data, allowing us to carefully select subjects for hiPSC based disease model development. This clinical-genetic stratification is essential to ensure that cellular models display disease and therapy relevant phenotypes. hiPSC reprogramming is undertaken by an internationally respected centre, providing robust, reliable and timely delivery of hiPSCs; ensures the biorepository only houses quality assured hiPSC lines; and reduces unwanted variability in assays. We have leading experts in hiPSC differentiation, providing protocols with over 99% efficiency in producing cortical excitatory neurons and cardiomyocytes, which following up-scaling will meet demands of high throughput assays. StemBANCC will deliver a comprehensive ‘omics’ dataset on over 1500 stem cell lines. This includes cells taken at different lineage stages, after therapeutic challenge, monogenic and complex variants, and with matched isogenic controls. The integration of this network/pathway data will define core etiopathological processes, therapeutic generality, reveal on- and off-target effects, allow candidate therapeutic repositioning and decouple tolerance and toxicity pathways. The large-scale integrated datasets then directly guide the disease specific targeted assays, designed to maximize utility in low and high- through compound screening programs. Assay development undertaken by the StemBANCC proposed central test facility thereby provides the final component of our hiPSC platform for drug discovery, development and safety.

Keywords: stem cells,ipsc,diabetes,neurological,toxicology,assay development,biobank
Combatting Bacterial Resistance in Europe (COMBACTE-NET)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: United Kingdom,Netherlands,Belgium,Germany,France,France,Germany,France,Belgium,Switzerland,Germany,Netherlands,United Kingdom,France,Sweden,Belgium,Spain,France,Sweden,Greece,Germany,Germany,France,Netherlands,Spain,Spain,Israel,Portugal,Italy,France
Call:  (IMI-JU-06-2012, 2012)
Start date: 2013-01-01
End date: 2021-02-28
Duration (months): 98.0
Total project cost (EUR): 220954266.0
EU funding (EUR): 109433010.0
Participants: 39
Project status: CLOSED

The emergence of Antibiotic-resistant bacteria (ARB) is a global problem, having recently been elevated to the top three threats identified by the World Health Organisation (WHO), and subject of numerous national and international government activities, including the Trans-Atlantic Task Force on Antimicrobial Resistance established by the US and EU presidencies. The estimated costs of ARB are around € 1.5 Billion per year in Europe, with an estimated 25,000 deaths (European Center for Disease prevention and Control/European Medicines Agency “time to react”). While the threat of antimicrobial resistance is growing, so are the challenges to bringing forward new therapeutic options for patients infected with resistant organisms. There is a need for a better understanding of how antimicrobial resistance is evolving globally, of what novel molecular mechanisms can be exploited as new forms of antimicrobial therapy and of how to more efficiently develop new treatments so they can be more rapidly brought to patients in need. The over-arching concept of New Drugs for Bad Bugs (ND4BB) is to create an innovative public-private collaborative partnership that will positively impact all aspects of ARB through the discovery and development of novel agents for the treatment, prevention and management of patients with bacterial infections. COMBACTE is one of the first projects to be launched under this programme with the aim of developing a broad European network of fully capable and Good Clinical Practice (GCP) compliant clinical investigation sites to execute clinical trials enabling the registration of novel agents to be used in the treatment of patients with bacterial infections. The growth and application of the network will be supported with robust microbiologic surveillance data and clinical epidemiologic data. To reduce the time and or cost of clinical development, novel clinical trial designs will be outlined and supported through analysis of publically available and consortium-shared non-clinical and clinical data. In addition to executing the initial set of clinical trials, investigations of patient and pathogen-related biomarkers and the logistical and decision making impact of rapid diagnostics will be conducted.

Keywords: antibiotic,antibacterial resistance,clinical trial,biomarker,diagnostics
Intelligent Assessment of Pharmaceutical in the Environment (IPIE)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative
Action type: Collaborative project
Partnership: IMI (Art-185)
Countries involved: Germany,Spain,United Kingdom,Germany,Germany,Netherlands,Germany,United Kingdom,Germany,United Kingdom,United States,Belgium,Switzerland,Sweden,France,Germany,United Kingdom,Netherlands
Call:  (IMI-JU-11-2013, 2013)
Start date: 2015-01-01
End date: 2019-06-30
Duration (months): 54.0
Total project cost (EUR): 10345016.0
EU funding (EUR): 3000000.0
Participants: 26
Project status: CLOSED

Active pharmaceutical ingredients (APIs) can be released to the natural environment during the manufacturing process, following use by patients or when unused medicines are disposed of. As APIs are biologically active compounds concerns have been raised about the potential effects of APIs in the environment on human and environmental health. Over the past 15 years, a substantial amount of work has been done to determine the occurrence, fate, effects, and resulting risks of APIs in the environment and regulatory schemes have been developed requiring environmental risk assessments of all new APIs. However for most APIs currently in use, limited data are available on environmental risks and for new APIs, the testing regimes may not always be optimum. The aim of this project therefore is to develop frameworks that utilise information from toxicological studies, pharmacological mode of action and in silico models to support more intelligent environmental testing of pharmaceuticals in development and to prioritise legacy pharmaceuticals for full environmental risk assessment and/or environmental (bio) monitoring. The aim will be delivered through a number of specific objectives: 1) to review existing approaches for prioritisation and mode of action based intelligent testing of APIs and develop improved frameworks; 2) to establish a high quality database on the properties, environmental fate characteristics and ecotoxicity of APIs; 3) to develop methods for estimating external and internal exposure to APIs for different scenarios; 4) to develop methods and models for predicting ecotoxicological responses to APIs; 5) to validate the developed models, concepts and frameworks using targeted experiments; and 6) to develop a software system to support intelligent testing and prioritisation of APIs in the environment. These objectives will be delivered by a world leading consortium comprising experts in data management and computational modelling, pharmacology, ecotoxicology, environmental chemistry, predictive (eco)toxicology, prioritisation and intelligent testing methodologies and environmental risk assessment.

Keywords: pharmaceutical,prioritisation,intelligent testing,ecotoxicology,environmental exposure,models
Joint Equipment and Materials for System-in-Package and 3D-Integration (JEMSIP_3D)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Electronic Numerical Integrator and Computer
Action type: Collaborative project
Partnership: ENIAC (Art-185)
Countries involved: Germany,France,Germany,France,Netherlands,Netherlands,Germany,France,Norway,Hungary,Netherlands,Germany,Netherlands,Sweden,Germany
Call:  (JU-ENIAC-2008-1, 2008)
Start date: 2009-04-01
End date: 2012-03-01
Duration (months): 35.0
Total project cost (EUR): 25625273.0
EU funding (EUR): 4279419.0
Participants: 20
Project status: CLOSED

The objective of the project « Joint Equipment & Materials for System-in-Package and 3D Integration » is to validate technological solutions for the fabrication of high value-added heterogeneous components and systems. This theme, generally known as “More Than Moore”, intends to gather within a unique system a set of various functions, implemented with elementary components, those generally being from various origins and technologies (memories, logic, sensors, actuators, wireless communication…). Numerous feasibility studies around the world already concluded positively at the R&D level, and Europe has advantages in the supply chain and a leading position that it should maintain. For that purpose, the JEMSiP_3D project gathers the majority of the European actors of the domain: material providers, laboratories, research centers and manufacturers of equipments, components and systems. The project is structured around 5 themes: ·Methodology and evaluation tools to integrate elementary components in 3D systems. ·3D technologies and integration processes onto materials and non-Si substrates ·3D technologies and integration processes onto Si, using processes closely deriving from microelectronics ·Test equipment, measurement protocols and reliability methodologies for integrated 3D systems ·Performance evaluation and equipment validation for volume production equipment and generic manufacturing This horizontal project targeting the implementation of production tools for 3D integration and associated technologies will be a direct support to the projects presented to the 6 applicative sub-programs defined in ENIAC work program.

Keywords: system-in-package,3d integration,equipment,materials,more than moore
Central Nervous System Imaging (CSI)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Electronic Numerical Integrator and Computer
Action type: Collaborative project
Partnership: ENIAC (Art-185)
Countries involved: Italy,Netherlands,Austria,Italy,Hungary,Austria,Hungary,Hungary
Call:  (ENIAC-2009-1, 2009)
Start date: 2010-03-01
End date: 2013-02-01
Duration (months): 35.0
Total project cost (EUR): 14641993.0
EU funding (EUR): 2445213.0
Participants: 15
Project status: CLOSED

Diseases affecting the brain and the central nervous system are among those with the greatest impact on our society. The ENIAC JU project CSI aims to advance the state of the art in three-dimensional (3D) medical-imaging platforms to improve the efficiency of the diagnosis and therapy of these serious diseases. The objective of the project is to develop an innovative yet simple and low-cost smart 3D imaging system suitable for use in ambulatory or domestic settings, able to enhance early diagnostic accuracy and boost the prevention capability while reducing the total cost of the equipment.
European Researchers’ Night Innsbruck - Bozen/Bolzano (EURENI)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: European Researchers' Night
Action type: Coordination and support actions
Countries involved: Austria
Call:  (FP7-PEOPLE-2007-5-1-1-NIGHT, 2007)
Start date: 2007-07-01
End date: 2008-01-31
Duration (months): 7.0
Total project cost (EUR): 123600.0
EU funding (EUR): 40000.0
Participants: 3
Project status: CLOSED

Research effects mankind like almost no other process on earth. The main objective of the European Researchers´ Night on the 28 September 2007 is to bring research closer to the public and to start a direct and reciprocal dialog between researchers and the large public. The University of Innsbruck, the Medical University of Innsbruck and the Tyrolean Future Foundation (Austria) as well as the EURAC, the Free University of Bozen/Bolzano and the TIS, Bozen/Bolzano (Italy) have a lot of experience in science communication activities and wide networking. These partners, who are used to work together for events of the same size as the Researchers´ Night, want to show that researchers are a normal group of the population through close dialogs and performances (e.g. experiments) with and for the audience. The event will be addressed to the public through broad PR & Marketing activities. We want to show the European dimension through the participation of researchers being involved in projects of the European Framework Programmes, by using the title EUROPEAN RESEARCHERS´ NIGHT and through a close cooperation with the Europe Direct Tirol of the Tyrolean government (European Information Office) for information and PR activities. We want to be action orientated and surprising through different contests (e.g. drawing competition), activities for children and young people, games, eating & meeting points as well as music performances at different locations. With these activities we will offer an informal, pleasant, enjoyable and attractive atmosphere. We will involve a lot of different institutes form different faculties and different partners of business and industry.

Keywords: science communication,researchers night
RESEARCHERS AGAINST DEGRADING ENVIRONMENT (RADE)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: European Researchers' Night
Action type: Coordination and support actions
Countries involved: Greece
Call:  (FP7-PEOPLE-2007-5-1-1-NIGHT, 2007)
Start date: 2007-06-01
End date: 2007-11-30
Duration (months): 6.0
Total project cost (EUR): 72610.0
EU funding (EUR): 65220.0
Participants: 2
Project status: CLOSED

The Laboratory of Environmental Chemistry of NKUA and the Hellenic Oceanographers’ Association, in the framework of the European programme ‘Researchers’ night 2007’, intend to organize an open-air event, called ‘Researchers Against Degrading Environment’ (R.A.D.E.) on Friday, September 28th 2007. The event will be held in the municipality of Elefsina, a historical and industrial town situated on the western coast of Attica and will include a wide range of both scientific and entertaining activities, organized in a multi- purpose sense, including the “Draw a Researcher” competition. The environmentally orientated activities will address people of all ages and backgrounds. The strategic objective of R.A.D.E. is to attract the interest of a mass audience of approximately 1500 attendees and introduce them to researchers in a festive way. It will give them the chance to socialize with scientists, uncovering the social aspect of their personality, and therefore comprehend that they are “normal” human beings. Additionally, R.A.D.E. will demonstrate that European citizens can benefit from the support of the European Union by means of various actions such as Marie Curie Schemes and awards. The project will attempt to raise the locals’ environmental awareness through the activities included, consequently demonstrating that environmental research can be an integrated part of ordinary people’s life and not just a matter of professionals. Finally, through the R.A.D.E. event we wish to establish a fall rendezvous between researchers and the public.

Keywords: environmental awareness,festive,eu beneficiaries,elefsina,mass audience,public/researchers contact